MBX Biosciences Presents Positive Results from Phase 1 Study of MBX 2109 in Late-Breaking Oral Presentation at the American Society for Bone and…


MBX 2109 was generally well-tolerated across all dosing cohorts

Read more here:
MBX Biosciences Presents Positive Results from Phase 1 Study of MBX 2109 in Late-Breaking Oral Presentation at the American Society for Bone and...

Related Posts